Cullinan Therapeutics Inc News - CGEM

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Current Report Filing (8-k)

false 0001789972 0001789972 2023-02-13 2023-02-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Annual Statement of Changes in Beneficial Ownership (5)

FORM 5 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Amended Statement of Ownership (sc 13g/a)

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934(Amendment No.: 1)* Name...

Statement of Ownership (sc 13g)

us2300311063_020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a...

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CGEM News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

Amended Statement of Ownership (sc 13g/a)

Annual Statement of Changes in Beneficial Ownership (5)

Amended Statement of Ownership (sc 13g/a)

Statement of Ownership (sc 13g)

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Statement of Changes in Beneficial Ownership (4)

CGEM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM) News

Cullinan Therapeutics Inc (CGEM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CGEM News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

Amended Statement of Ownership (sc 13g/a)

Annual Statement of Changes in Beneficial Ownership (5)

Amended Statement of Ownership (sc 13g/a)

Statement of Ownership (sc 13g)

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Statement of Changes in Beneficial Ownership (4)

CGEM Discussion

Your Recent History